Report for: Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease

Title	Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease
Published in	Cochrane database of systematic reviews, November 2013
DOI	10.1002/14651858.cd002309.pub4
Pubmed ID	24190161
Authors	Chong, Jimmy, Leung, Bonnie, Poole, Phillippa
Abstract	Chronic obstructive pulmonary disease (COPD) is associated with cough, sputum production or dyspnoea and a reduction in lung function, quality of life and life expectancy. Apart from smoking cessation, there are no other treatments that slow lung function decline. Roflumilast and cilomilast are oral phosphodiesterase 4 (PDE4) inhibitors proposed to reduce the airway inflammation and bronchoconstriction seen in COPD.

View on publisher site Alert me about new mentions

Twitter Demographics

The data shown below were collected from the profiles of 12 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Geographical breakdown

Country	Count	As %
United Kingdom	3	25%
Indonesia	1	8%
Spain	1	8%
Unknown	7	58%

Demographic breakdown

Type	Count	As %
Members of the public	9	75%
Science communicators (journalists, bloggers, editors)	1	8%
Practitioners (doctors, other healthcare professionals)	1	8%
Scientists	1	8%

Mendeley readers

The data shown below were compiled from readership statistics for 163 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country	Count	As %
United Kingdom	2	1%
United States	1	<1%
Italy	1	<1%
Unknown	159	98%

Demographic breakdown

Readers by professional status	Count	As %
Student > Master	38	23%
Researcher	25	15%
Student > Postgraduate	14	9%
Student > Bachelor	14	9%
Other	11	7%
Other	28	17%
Unknown	33	20%

Readers by discipline	Count	As %
Medicine and Dentistry	57	35%
Psychology	22	13%
Nursing and Health Professions	11	7%
Social Sciences	10	6%
Engineering	4	2%
Other	16	10%
Unknown	43	26%

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 July 2017.

All research outputs

#1,753,521

of 23,566,295 outputs

Outputs from Cochrane database of systematic reviews

#3,974

of 12,743 outputs

Outputs of similar age

#17,082

of 216,447 outputs

Outputs of similar age from Cochrane database of systematic reviews

#91

of 243 outputs

Altmetric has tracked 23,566,295 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.

So far Altmetric has tracked 12,743 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 33.1. This one has gotten more attention than average, scoring higher than 68% of its peers.

Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 216,447 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.

We're also able to compare this research output to 243 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.

Cochrane Database of Systematic Reviews

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease

About this Attention Score

Mentioned by

Citations

Readers on

Twitter Demographics

Geographical breakdown

Demographic breakdown

Mendeley readers

Geographical breakdown

Demographic breakdown

Attention Score in Context